Companies › Thirty Respiratory
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Respiratory, Infectious disease; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RESP30TB Nitric oxide agent | – | Phase 2 | Pulmonary Tuberculoses | Nov 2026 |
| RESP302 Nitric oxide agent for inhalation | – | Phase 1 | Non-Cystic Fibrosis Bronchiectasis | Feb 2028 |
| RESP303 Nitric oxide agent for inhalation | – | Phase 1 | Non-Cystic Fibrosis Bronchiectasis | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07073638 | RESP30TB | Phase 2 | Pulmonary Tuberculoses | Infectious disease | Nov 2026 |
| NCT06663176 | RESP302 | Phase 1 | Non-Cystic Fibrosis Bronchiectasis | Respiratory | Feb 2028 |
| NCT06663176 | RESP303 | Phase 1 | Non-Cystic Fibrosis Bronchiectasis | Respiratory | Feb 2028 |
No annotated target.
–
Mundipharma Research Vicore Pharma SpliSense GEn1E Lifesciences Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.